TBL 5: HCV

Question 1

What factors contribute to a higher prevalence of liver disease in AI/AN populations than non-indigenous populations?

Answer 1

ACCESS: lack of healthcare professionals (needing gastroenterologist & transportation) was a bigger deal than risky behavior

Inability to administer treatments:

Question 2

How is HCV transmitted?

Answer 2

Bloodborne pathogen:
IV drug usage
Sexual contact
blood transfusions prior to 1990

Question 3

How is HCV diagnosed?

Answer 3

ELISA Anti-HCV antibody, or RNA genome detection via RT-PCR (GOLD STANDARD)

Question 4

What HCV drug is teratogenic?

Answer 4

Ribidvarin

Question 5

What HCV drug should be avoided w/ people who have liver cirrhosis?

Answer 5

IFN-a

Question 6

How does IFN alpha work?

Answer 6

j

Question 7

How does ribivarin work?

Answer 7

Ribonucleic analog: inhibits viral RNA pol and protein synth

booster for other drug concentrations by inhibiting CYP3A4(protease inhibitors are metabolized by CYP3A4, so ritonavir increases their concentration)

*causes increased hemolysis> increased bilirubin

Question 8

What is ABT 450?

Answer 8

Protease inhibitor

is an acylsulfonamide[1] inhibitor of the NS3-4A serine protease

Question 9

What is ombitasvir?

Answer 9

targets non-structural protein 5A, which normally is responsible for allowing replication of HCV and is a key regulator in cell function

Question 10

What is dasabuvir?

Answer 10

Non-nucleoside NS5B polymerase inhibitor which normally has the key function of replicating the HCV’s viral RNA by using the viral positive RNA strand as its template and catalyzes the polymerization of ribonucleoside triphosphates (rNTP) during RNA replication